FibroGen (FGEN) Tops Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update
November 8, 2016 4:03 PM ESTCompletes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD
Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time
SAN FRANCISCO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a research-based biopharmaceutical company, today reported financial results for the quarter ended September 30, 2016 and provided an update on the companys recent developments.
The completion of enrollment in our Phase 3 roxadustat studies in China is a... More
